Steve Perrin PhD, CEO and CSO of ALS TDI, talks Gilenya, other emerging immunomodulators and their potential to treat ALS going forward. Read more: http://blogs.als.net/post/2013/02/12/Gilenya-giving-ALS-the-fingo.aspx